Federal framework
Does a compounded drug need a patient-specific prescription?
For a state-licensed 503A pharmacy, yes: the exemption at 21 U.S.C. § 353a applies where the drug is compounded for an identified individual patient on a valid prescription order, so a supply naming no patient falls outside it. For a facility registered with FDA as an outsourcing facility under section 503B, no — which is why one route can fill a shelf and the other cannot.
What does the statute condition on?
An identified individual patient, named before the exemption applies.
Section 353a(a) exempts a compounded drug from three requirements of the Federal Food, Drug, and Cosmetic Act — current good manufacturing practice, adequate directions for use, and new drug approval — where the drug is "compounded for an identified individual patient based on the receipt of a valid prescription order." The condition is doing structural work. Remove the identified patient and the exemption does not attach, and without the exemption the preparation is measured against requirements no compounded drug could meet.
This is why the question matters commercially rather than academically. It is not a documentation preference. It is the thing that makes the activity lawful at all for a state-licensed pharmacy.
What is the limited exception?
Compounding ahead of the order, not compounding without one.
Section 353a(a)(2) permits compounding "in limited quantities before the receipt of a valid prescription order" where that is done based on a history of the pharmacist receiving valid prescription orders within an established relationship between the prescriber, the patient and the pharmacist. The stock exists before the order does — but it is still released against a patient-specific order when one arrives.
The state rules we have read say the same thing in their own words. Georgia's compounding rule permits anticipatory preparation and provides that such stock shall not be dispensed until a valid patient-specific order is received. North Carolina's rule carries the identical limb. That distinction has its own page at anticipatory compounding compared with office use, because conflating the two is the most common way this exception is misread.
Where does the requirement not apply?
Section 353b, and this is the whole reason a second pathway exists.
The outsourcing-facility exemption does not require a patient-specific prescription. In exchange the facility registers with FDA, complies with current good manufacturing practice, reports adverse events, submits to FDA inspection on a risk-based schedule, and meets the labelling requirements the section imposes. The trade is explicit in the statutory design: a heavier compliance burden on the facility, in return for the ability to supply product that names no patient.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Patient-specific prescription required for the exemption | Yes | No |
| Credentialled by | A state board of pharmacy | Registration with FDA, plus the state credentials required where it ships |
| Manufacturing-practice requirement | Exempted by section 353a | Applies; the section does not exempt it |
| Can supply stock that names no patient | Not under this exemption | Yes, subject to the section's own conditions |
Does a state permission override it?
No, and the rules that condition themselves on federal law say so in their own text.
Several of the state rules we have read either incorporate the federal provision or condition their permission on compliance with applicable federal law. North Carolina's office-use rule permits a pharmacy to supply compounded drug products to prescribers and then adds that such compounding for office use "shall comply with applicable federal law." Ohio's compounding rule directs a pharmacy to comply with 21 U.S.C. § 353a, while a separate Ohio statute carves out a narrow office-use lane — a genuine tension the Board has not published guidance reconciling. New Jersey's rules bar the practice for human use "except to the extent permitted by Federal law."
Why is that phrasing so often misread?
Because "permitted, consistent with federal law" reads like a permission with a footnote, when it is a permission with a condition.
A state rule phrased that way has not created a federal safe harbour. It has handed the question back to the federal provision, which conditions on the identified individual patient. Louisiana's own regulation makes the point against itself, warning that the Board's rules cannot legitimise an activity federal law does not permit and that pharmacists engaging in it remain subject to federal enforcement.
So when a supplier cites a state rule containing that phrase, the rule text is only half of the citation. The other half is which federal provision they say is satisfied, and how.
Who may write the prescription?
A different question, decided somewhere else, and the distinction is worth holding onto.
Section 353a keys on the existence of a valid prescription order. It does not say who is authorised to issue one — that comes from each state's medical, nursing and other practice acts, and it varies. The compounding rules we have read reflect this by keying on authority rather than on title: North Carolina authorises supply to "practitioners authorized by law to prescribe drugs," and Ohio's carve-out refers to "a licensed health professional authorized to prescribe drugs."
So the federal requirement tells you a prescription is needed and the state tells you whether yours is a valid one. A national answer to the first does not produce a national answer to the second.
What does this mean in practice?
Three consequences that decide how an order should be structured.
A patient-specific order can travel to a practice. The pharmacy compounds against a prescription written for a named patient and delivers to the practice for administration. Illinois expressly excludes that delivery from its own definition of office use, which is a useful reminder that it is a different transaction rather than a lighter form of the same one.
Stock that names no patient needs the other pathway, and then needs the destination state's own answer about whether the practice may hold it.
"Consistent with federal law" is a condition, not a permission. When a supplier cites a state rule containing that phrase, the next question is which federal provision they say is satisfied, and how.
Each state's rule text, citation and last-reviewed date is in the state-by-state office-use guide, and the definitions underneath all of it are set out at 503A pharmacies and 503B outsourcing facilities compared. One consequence of the exemption structure described above is worth reading on its own: because both provisions work by exempting a preparation from the approval requirement, no compounded preparation is ever approved — set out at why a compounded drug is never FDA-approved. One-sentence definitions of the three terms this page turns on are in the glossary: patient-specific prescription, office use and anticipatory compounding.